Skip to main content
NameEmailPhD ProgramResearch InterestPublications
Lai, Samuel
WEBSITE
EMAIL
PUBLICATIONS

PHD PROGRAM
Microbiology & Immunology, Oral & Craniofacial Biomedicine, Pharmaceutical Sciences

RESEARCH INTEREST
Biomaterials, Biophysics, Drug Delivery, Immunology, Nanomedicine, Pathogenesis & Infection

Our dynamic group are broadly involve in three topics: (i) prevention of infectious diseases by harnessing interactions between secreted antibodies and mucus, (ii) immune response to biomaterials, and (iii) targeted delivery of nanomedicine.  Our group was the first to discover that secreted antibodies can interact with mucins to trap pathogens in mucus.  We are now harnessing this approach to engineer improved passive and active immuniation (i.e. vaccines) at mucosal surfaces, as well as understand their interplay with the mucosal microbiome.  We are also studying the adaptive immune response to polymers, including anti-PEG antibodies, and how it might impact the efficacy of PEGylated therapeutics.  Lastly, we are engineering fusion proteins that can guide targeted delivery of nanomedicine to heterogenous tumors and enable personalized medicine.

Lawrence, David S
WEBSITE
EMAIL
PUBLICATIONS

PHD PROGRAM
Chemistry, Pharmaceutical Sciences, Pharmacology

RESEARCH INTEREST
Cancer Biology, Cell Biology, Cell Signaling, Chemical Biology, Molecular Medicine

Living cells have been referred to as the test tubes of the 21st century. New bioactive reagents developed in our lab are designed to function in cells and living organisms. We have prepared enzyme inhibitors, sensors of biochemical pathways, chemically-altered proteins, and activators of gene expression. In addition, many of these agents possess the unique attribute of remaining under our control even after they enter the biological system. In particular, our compounds are designed to be inert until activated by light, thereby allowing us to control their activity at any point in time.

Lee, Andrew
WEBSITE
EMAIL
PUBLICATIONS

PHD PROGRAM
Biochemistry & Biophysics, Pharmaceutical Sciences

RESEARCH INTEREST
Biochemistry, Biophysics, Chemical Biology, Computational Biology, Structural Biology

We study protein structure and dynamics as they relate to protein function and energetics. We are currently using NMR spectroscopy (e.g. spin relaxation), computation, and a variety of other biophysical techniques to gain a deeper understanding of proteins at atomic level resolution.  Of specific interest is the general phenomenon of long-range communication within protein structures, such as observed in allostery and conformational change.  A. Lee is a member of the Molecular & Cellular Biophysics Training Program.

Redinbo, Matt
WEBSITE
EMAIL
PUBLICATIONS

PHD PROGRAM
Biochemistry & Biophysics, Bioinformatics & Computational Biology, Chemistry, Microbiology & Immunology, Oral & Craniofacial Biomedicine, Pathobiology & Translational Science, Pharmaceutical Sciences, Pharmacology

RESEARCH INTEREST
Bacteriology, Biochemistry, Bioinformatics, Biophysics, Cancer Biology, Chemical Biology, Computational Biology, Drug Delivery, Drug Discovery, Metabolism, Microbiology, Molecular Biology, Molecular Medicine, Pharmacology, Plant Biology, Structural Biology, Systems Biology, Toxicology

We are interested in unraveling the molecular basis for human disease and discover new treatments focused on human and microbial targets. Our work extends from atomic-level studies using structural biology, through chemical biology efforts to identify new drugs, and into cellular, animal and clinical investigations. While we are currently focused on the gut microbiome, past work has examined how drugs are detected and degraded in humans, proteins designed to protect soldiers from chemical weapons, how antibiotic resistance spreads, and novel approaches to treat bacterial infections. The Redinbo Laboratory actively works to increase equity and inclusion in our lab, in science, and in the world. Our lab is centered around collaboration, open communication, and trust. We welcome and support anyone regardless of race, disability, gender identification, sexual orientation, age, financial background, or religion. We aim to: 1) Provide an inclusive, equitable, and encouraging work environment 2) Actively broaden representation in STEM to correct historical opportunity imbalances 3) Respect and support each individual’s needs, decisions, and career goals 4) Celebrate our differences and use them to discover new ways of thinking and to better our science and our community

Singleton, Scott
WEBSITE
EMAIL
PUBLICATIONS

PHD PROGRAM
Pharmaceutical Sciences

RESEARCH INTEREST
Bacteriology, Biochemistry, Chemical Biology, Drug Discovery, Pharmacology

The Singleton Laboratory is interested in understanding the molecular basis for the develoment and transmission of microbial drug resistance and the discovery and exploitation of new strategies for controlling drug-resistant microorganisms. We develop and adapt synthetic chemistry and synthetic biology methods to provide new molecular tools — both biologically active small molecules and innovative platforms — for hypothesis-driven biological research and pharmaceutical discovery. These foundations of our program offers both chemically-oriented and biologically-oriented researchers new opportunities for the development of integrated, multi-disciplinary knowledge and technologies.

Tropsha, Alexander
WEBSITE
EMAIL
PUBLICATIONS

PHD PROGRAM
Bioinformatics & Computational Biology, Neuroscience, Pharmaceutical Sciences, Toxicology

RESEARCH INTEREST
Bioinformatics, Computational Biology, Molecular Medicine, Structural Biology, Toxicology

The major area of our research is Biomolecular Informatics, which implies understanding relationships between molecular structures (organic or macromolecular) and their properties (activity or function). We are interested in building validated and predictive quantitative models that relate molecular structure and its biological function using statistical and machine learning approaches. We exploit these models to make verifiable predictions about putative function of untested molecules.

Zhang, Qisheng
WEBSITE
EMAIL
PUBLICATIONS

PHD PROGRAM
Pharmaceutical Sciences

RESEARCH INTEREST
Biochemistry, Cell Signaling, Chemical Biology, Pharmacology, Translational Medicine

Our lab studies lipid signaling pathways that are involved in development and diseases by developing novel chemical probes and technologies. As key components of cellular membranes, lipids also serve as signaling molecules and modify functions of proteins through either covalent or non-covalent interactions. Dys-regulation of lipid signaling has been correlated with various diseases including cancer, diabetes, and neurodegenerative diseases. Consequently, many lipid-related proteins or processes have been used as therapeutic targets. However, lipids are dynamically metabolized and transported, making it difficult to illustrate the roles of lipids in development and diseases with limited availability of probes and technologies for lipid studies. The active projects in the lab include: 1) develop novel technologies to synthesize complex lipids, particularly phosphatidylinositides, and identify their interacting proteins in live cells; 2) develop new small molecule sensors and inhibitors for lipid metabolic enzymes such as PI3K and PLC; and 3) investigate cellular functions of lipids on different processes, particularly those regulated by small GTPases.

Hathaway, Nathaniel A.
WEBSITE
EMAIL
PUBLICATIONS

PHD PROGRAM
Genetics & Molecular Biology, Pharmaceutical Sciences

RESEARCH INTEREST
Cancer Biology, Cell Biology, Chemical Biology, Drug Discovery, Molecular Medicine

The Hathaway lab is focused on understanding the biological events responsible for dynamically regulating the selective expression of the mammalian genome. In multicellular organisms, genes must be regulated with high precision during stem cell differentiation to achieve normal development. Pathologically, the loss of proper gene regulation caused by defects in chromatin regulatory enzymes has been found to be a driving force in cancer initiation and progression. My lab uses a combination of chemical biology and cell biology approaches to unravel the molecular mechanisms that govern gene expression. We utilize new tools wielding an unprecedented level of temporal control to visualize changes in chromatin structure and function in mammalian cells and animal models. In addition, we seek to identify small molecule inhibitors that are selective for chromatin regulatory enzymes with the potential for future human therapeutics.

Tarantino, Lisa M.
WEBSITE
EMAIL
PUBLICATIONS

PHD PROGRAM
Genetics & Molecular Biology, Neuroscience, Pharmaceutical Sciences

RESEARCH INTEREST
Behavior, Genetics, Genomics, Molecular Biology, Neurobiology, Pharmacology, Systems Biology

The Tarantino lab studies addiction and anxiety-related behaviors in mouse models using forward genetic approaches. We are currently studying a chemically-induced mutation in a splice donor site that results in increased novelty- and cocaine-induced locomotor activity and prolonged stress response. We are using RNA-seq to identify splice variants in the brain that differ between mutant and wildtype animals. We are also using measures of initial sensitivity to cocaine in dozens of inbred mouse strains to understand the genetics, biology and pharmacokinetics of acute cocaine response and how initial sensitivity might be related to addiction. Finally, we have just started a project aimed at studying the effects of perinatal exposure to dietary deficiencies on anxiety, depression and stress behaviors in adult offspring. This study utilizes RNA-seq and a unique breeding design to identify parent of origin effects on behavior and gene expression in response to perinatal diet.

Ainslie, Kristy M.
WEBSITE
EMAIL
PUBLICATIONS

PHD PROGRAM
Microbiology & Immunology, Pharmaceutical Sciences

RESEARCH INTEREST
Biomaterials, Drug Delivery, Immunology, Nanomedicine

We have several areas of research interest broadly in the area of immunomodulation using micro/nanoparticles and other carrier systems.  This can include development of traditional vaccines, therapeutic autoimmune vaccines and classic drug delivery platforms targeted to bacterial, viral or parasitic host cells.  To this end, we also seek to develop new materials and platforms optimal for use in modulating immune responses as well as developing scalable production of micro/nanoparticles.